Ooi Jun, Iseki Tohru, Takahashi Satoshi, Tomonari Akira, Takasugi Kashiya, Shimohakamada Yoko, Yamada Toshiki, Ishii Koji, Ohno Nobuhiro, Nagamura Fumitaka, Uchimaru Kaoru, Tojo Arinobu, Asano Shigetaka
Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Blood. 2004 Jan 15;103(2):489-91. doi: 10.1182/blood-2003-07-2420. Epub 2003 Aug 21.
We report the results of unrelated cord blood transplantation (CBT) for 18 adult patients with de novo acute myeloid leukemia (AML). The median age was 43 years, the median weight was 55.2 kg, and the median number of cryopreserved nucleated cells was 2.51 x 107/kg. Seventeen patients had myeloid reconstitution and the median time to more than 0.5 x 109/L absolute neutrophil count was 23 days. A self-sustained platelet count more than 50 x 109/L was achieved in 16 patients at a median time of 49 days. Acute graft-versus-host disease (GVHD) above grade II occurred in 11 of 17 evaluable patients and chronic GVHD occurred in 14 of 17 evaluable patients. Fourteen patients are alive and free of disease at between 185 and 1332 days after transplantation. The probability of disease-free survival at 2 years was 76.6%. These results suggest that adult AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
我们报告了18例成年初发急性髓系白血病（AML）患者接受非血缘脐血移植（CBT）的结果。中位年龄为43岁，中位体重为55.2kg，冷冻保存的有核细胞中位数为2.51×10⁷/kg。17例患者实现了髓系重建，中性粒细胞绝对计数超过0.5×10⁹/L的中位时间为23天。16例患者血小板计数持续维持超过50×10⁹/L，中位时间为49天。17例可评估患者中有11例发生了II级以上急性移植物抗宿主病（GVHD），17例可评估患者中有14例发生了慢性GVHD。14例患者在移植后185至1332天存活且无疾病。2年无病生存率为76.6%。这些结果表明，没有合适的血缘或非血缘骨髓供者的成年AML患者应被视为CBT的候选者。
